Caption Management, LLC Viridian Therapeutics, Inc.\De Call Options Transaction History

Caption Management, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $2.33 Million - $4.48 Million	192,000 New	192,000 $4.37 Million
Q1 2024 May 15, 2024	BUY	$17.09 - $23.82 $769,050 - $1.07 Million	45,000 New	45,000 $787,000
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $952,454 - $1.25 Million	42,200 Added 84.4%	92,200 $2.19 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $1.25 Million - $1.88 Million	50,000 New	50,000 $1.27 Million
Q3 2021 Nov 12, 2021	BUY	$10.69 - $18.2 $384,840 - $655,200	36,000 New	36,000 $592,000

178

76.6M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $770M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.